Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Sultiam (ATC-Code nach WHO: N03AX03)
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Sultiam (ATC-Code nach WHO: N03AX03)
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
20 / 100
Risk factors
Purchasing volume is unknown and depends on prescription behavior and patient numbers. No minimum volume guaranteed.
The contracting authority may terminate the Open-House procedure early if exclusive agreements are concluded, typically...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Strong opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Dec 2027
- Supply of Sultiam film tablets (50 mg and 200 mg) for AOK PLUS.
- Non-exclusive discount agreement under § 130a Abs. 8 SGB V.
Show full summary
Non-exclusive pharmaceutical discount agreement for Sultiam (ATC N03AX03) film tablets 50 mg and 200 mg via an Open-House model by AOK PLUS for Saxony and Thuringia. The contract runs until 31 Dec 2027. No minimum quantities, no exclusivity, and no negotiations. Bidders must meet eligibility criteria and submit via DTVP portal. First submission deadline is 5 Mar 2026; late submissions accepted for subsequent deadlines.
Risks
Purchasing volume is unknown and depends on prescription behavior and patient numbers. No minimum volume guaranteed.
The contracting authority may terminate the Open-House procedure early if exclusive agreements are concluded, typically...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Bidders must be pharmaceutical companies as defined in § 4 Abs. 18 AMG.
Administrative
- Must submit declaration of no conflicts of interest (Eigenerklärung zum Nichtvorliegen von Ausschlussgründen).
- Must submit declaration regarding Russia sanctions (Eigenerklärung Russlandsanktionen).
Buyer
Name
AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Sultiam (ATC-Code nach WHO: N03AX03)
Non-exclusive framework agreement for Sultiam (ATC N03AX03) in film tablet form, strengths 50 mg and 200 mg, under § 130a Abs. 8 SGB V. Open-House model, no exclusivity, no guaranteed volumes.
Location
Duration
Category
Deadline
Award details
Selection criteria
Show original TED data
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 19 Feb 2026
- Notice type
- Contract notice — standard
- Languages
- German
Reference metadata
- Notice subtype
- 16
- Notice version
- 1
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 122067-2026
Documents (1)
Similar tenders
Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Ganirelix (ATC-Code: H01CC01).
Czechia – Pharmaceutical products – Léčivý přípravek ATC skupiny R03DX05 s účinnou látkou OMALIZUMAB
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V über Arzneimittel mit dem Wirkstoff Denosumab Xgeva (ATC-Code nach WHO: M05BX04)
Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit der Wirkstoffkombination aus Formoterol und Beclometason, ausgenommen Dosieraerosole mit der Wirkstärke 100µg/6µg (ATC-Code: R03AK08).
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Moldova – Pharmaceutical products – Achiziționarea centralizată a Reagenților pentru Investigații Clinice, Hematologice și PATOLOGICE conform necesităților IMSP - beneficiari pentru anul 2027
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
20 / 100
Risk factors
Purchasing volume is unknown and depends on prescription behavior and patient numbers. No minimum volume guaranteed.
The contracting authority may terminate the Open-House procedure early if exclusive agreements are concluded, typically...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications